Need help finding what you are looking for?
Contact Us
PUBLISHER: iGate Research | PRODUCT CODE: 1335151
PUBLISHER: iGate Research | PRODUCT CODE: 1335151
Global Influenza Vaccines Market, Persons Vaccinated, Key Company Analysis, Emerging Players Profile, Promising Influenza Vaccines in Clinical Development, Size, Share, Trends, Major Deals and Recent Developments - Forecast to 2030
PUBLISHED:
PAGES: 343 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The global influenza vaccines market is projected to reach US$ 10.9 Billion by 2030. Influenza viruses are considered as a major cause of morbidity and mortality worldwide. The Centers for Disease Control and Prevention (CDC) recommends routine seasonal influenza vaccination for all individuals 6 months of age and older. According to the World Health Organization (WHO), globally, about 3 to 5 million cases of severe influenza illness, and about 290,000 to 650,000 flu-related deaths are reported annually. The vast population base together with significantly low vaccination coverage in emerging markets, the introduction of new vaccines, rising government support for immunization and growing awareness of the value of influenza vaccine in preventing disease are the prominent factors that will drive the influenza vaccines market. The increasing R&D investments by leading market players, such as Sanofi, CSL Limited, and GlaxoSmithKline, for expanding manufacturing capabilities and focus on launching new vaccines will propel the market for influenza vaccines over the forecast period. However, shortage of vaccine supply due to the genetic assortment of the viral strains is surging the need for updating vaccines each year by the manufacturers. This is a major factor restraining market growth.
Recent Developments
- In July 2023, Sinovac Biotech Ltd. announced an alliance with Indonesian state-owned biopharmaceutical company PT Bio Farma, to serve Indonesia's domestic vaccine market as well as international market.
- In November 2022, Penn scientists developed a 20-subtype mRNA flu vaccine for protection against future flu pandemics.
- In October 2022, Novavax announced positive results from the Phase 1/2 clinical trial of its COVID-19-Influenza Combination (CIC) vaccine candidate.
- In March 2022, the Australian government invested more than US$ 100 million in the seasonal influenza vaccine to protect people at risk.
By Region: Influenza Vaccines Market and Forecast - Key Takeaways
- Geographically, North America is the largest market for influenza vaccines capturing over 50% market share in 2022.
- In the European region, almost all countries have national and/or regional vaccination policies or strategies for seasonal influenza in place.
- Asia is expected to be the fastest growing market for influenza vaccines, driven by the increasing population in the Asian countries, growing focus of the governments on enhancing healthcare facilities, rising incidence of seasonal influenza, and rising disposable income.
- Australasia accounted for least share of the influenza vaccines market in 2022.
By Country: Influenza Vaccines Market and Forecast - Key Takeaways
- On country basis, United States captured highest share of the influenza vaccines market.
- Japan is the second largest market for influenza vaccines.
- China, Brazil, Canada, Australia, Germany, UK, and India are the other leading markets for influenza vaccines.
- Poland is a country with one of the lowest influenza vaccination coverage rates among the EU member states.
By Company: Influenza Vaccines Market and Forecast - Key Takeaways
- In 2022, GlaxoSmithKline plc influenza vaccines sales were up 5% over the prior year.
- AstraZeneca influenza vaccines sales declined by 31% in 2022, owing to late start to the influenza season in Europe.
- In September 2022, Pfizer Inc. initiated the phase 3 clinical study for mRNA-based influenza vaccine. The study enrolled 25,000 U.S. adults aged 18 years and older.
- In 2021, Seqirus influenza vaccines sales increased by 37% over the prior year, driven by strong growth in seasonal influenza vaccines.
- In October 2022, Novavax announced positive results from the Phase 1/2 clinical trial of its COVID-19-Influenza Combination (CIC) vaccine candidate.
iGATE Research report titled "Global Influenza Vaccines Market, Persons Vaccinated, Key Company Analysis, Emerging Players Profile, Promising Influenza Vaccines in Clinical Development, Size, Share, Trends, Major Deals and Recent Developments - Forecast to 2030" provides a comprehensive assessment of the fast-evolving, high-growth influenza vaccines market landscape.
This 343 Page report with 149 Figures and 7 Tables has been analyzed from 8 viewpoints:
1. Influenza Vaccines Market, Persons Vaccinated and Forecast (2011 - 2030)
2. By Region - Influenza Vaccines Market, Persons Vaccinated and Forecast (2011 - 2030)
3. Country Wise Distribution - Influenza Vaccines Market, Persons Vaccinated and Forecast (2011 - 2030)
4. Influenza Vaccines Market - Key Company Analysis
5. Influenza Vaccines Market - Emerging Players Profile
6. Global Influenza Vaccines Market - Major Deals
7. Global Influenza Vaccines Market - Recent Developments
8. Global Influenza Vaccines Market - Driving Factors and Challenges
By Region - Influenza Vaccines Market, Persons Vaccinated and Forecast
1. North America
2. Latin America
3. Europe
4. Asia
5. Australasia
Country Wise Distribution - Influenza Vaccines Market, Persons Vaccinated and Forecast
1. United States
2. Canada
3. Brazil
4. Mexico
5. Germany
6. France
7. Italy
8. Spain
9. United Kingdom
10. Netherlands
11. Ireland
12. Denmark
13. Luxembourg
14. Sweden
15. Finland
16. Belgium
17. Poland
18. Norway
19. Australia
20. New Zealand
21. Japan
22. China
23. India
24. South Korea
25. Singapore
26. Hong Kong
27. Malaysia
28. Thailand
29. Indonesia
Influenza Vaccines Market - Key Company Analysis
1. GlaxoSmithKline (GSK)
2. Sanofi
3. Seqirus (CSL Limited)
4. Abbott
5. AstraZeneca
6. Gamma Vaccines Pty Ltd.
7. Hualan Bioengineering Co., Ltd
8. Mylan (Now Part of Viatris)
9. BioDiem
10. Shanghai Institute of Biological Products Co., Ltd.
Influenza Vaccines Market - Emerging Players Profile
1. Novavax
2. Medicago
3. Moderna Inc.
4. Pneumagen
5. Daiichi-Sankyo
6. FluGen
7. Imutex
8. EpiVax
9. Versatope Therapeutics, Inc.
10. BiondVax Pharmaceuticals Ltd.
11. BIKEN Co., Ltd.
12. Sinovac Biotech
13. Emergent BioSolutions
14. Osivax
15. Emergex Vaccines
Data Sources
iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.
Research Methodologies
Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.
Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases
Table of Contents
1. Executive Summary
2. Global - Influenza Vaccines Market and Forecast (2011 - 2030)
- 2.1 Global - Influenza Vaccines Market and Forecast
- 2.2 Global - Number of Persons Vaccinated with Influenza Vaccines and Forecast
3. Global - Influenza Vaccines Market Share and Forecast (2011 - 2030)
- 3.1 Influenza Vaccines Market Share and Forecast - Regional Analysis
- 3.2 Persons Vaccinated with Influenza Vaccines Share and Forecast - Regional Analysis
4. Influenza Vaccines Market, Persons Vaccinated and Forecast - By Region (2011 - 2030)
- 4.1 North America - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 4.1.1 North America - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 4.1.2 North America - Influenza Vaccines Market and Forecast
- 4.2 Latin America - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 4.2.1 Latin America - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 4.2.2 Latin America - Influenza Vaccines Market and Forecast
- 4.3 Europe - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 4.3.1 Europe - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 4.3.2 Europe - Influenza Vaccines Market and Forecast
- 4.4 Asia - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 4.4.1 Asia - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 4.4.2 Asia - Influenza Vaccines Market and Forecast
- 4.5 Australasia - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 4.5.1 Australasia - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 4.5.2 Australasia - Influenza Vaccines Market and Forecast
5. Influenza Vaccines Market, Persons Vaccinated and Forecast - Country Wise Distribution (2011 - 2030)
- 5.1 United States - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.1.1 United States - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.1.2 United States - Influenza Vaccines Market and Forecast
- 5.2 Canada - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.2.1 Canada - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.2.2 Canada - Influenza Vaccines Market and Forecast
- 5.3 Brazil - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.3.1 Brazil - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.3.2 Brazil - Influenza Vaccines Market and Forecast
- 5.4 Mexico - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.4.1 Mexico - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.4.2 Mexico - Influenza Vaccines Market and Forecast
- 5.5 Germany - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.5.1 Germany - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.5.2 Germany - Influenza Vaccines Market and Forecast
- 5.6 France - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.6.1 France - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.6.2 France - Influenza Vaccines Market and Forecast
- 5.7 Italy - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.7.1 Italy - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.7.2 Italy - Influenza Vaccines Market and Forecast
- 5.8 Spain - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.8.1 Spain - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.8.2 Spain - Influenza Vaccines Market and Forecast
- 5.9 United Kingdom - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.9.1 United Kingdom - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.9.2 United Kingdom - Influenza Vaccines Market and Forecast
- 5.10 Netherlands - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.10.1 Netherlands - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.10.2 Netherlands - Influenza Vaccines Market and Forecast
- 5.11 Ireland - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.11.1 Ireland - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.11.2 Ireland - Influenza Vaccines Market and Forecast
- 5.12 Denmark - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.12.1 Denmark - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.12.2 Denmark - Influenza Vaccines Market and Forecast
- 5.13 Luxembourg - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.13.1 Luxembourg - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.13.2 Luxembourg - Influenza Vaccines Market and Forecast
- 5.14 Sweden - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.14.1 Sweden - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.14.2 Sweden - Influenza Vaccines Market and Forecast
- 5.15 Finland - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.15.1 Finland - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.15.2 Finland - Influenza Vaccines Market and Forecast
- 5.16 Belgium - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.16.1 Belgium - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.16.2 Belgium - Influenza Vaccines Market and Forecast
- 5.17 Poland - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.17.1 Poland - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.17.2 Poland - Influenza Vaccines Market and Forecast
- 5.18 Norway - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.18.1 Norway - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.18.2 Norway - Influenza Vaccines Market and Forecast
- 5.19 Australia - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.19.1 Australia - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.19.2 Australia - Influenza Vaccines Market and Forecast
- 5.20 New Zealand - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.20.1 New Zealand - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.20.2 New Zealand - Influenza Vaccines Market and Forecast
- 5.21 Japan - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.21.1 Japan - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.21.2 Japan - Influenza Vaccines Market and Forecast
- 5.22 China - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.22.1 China - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.22.2 China - Influenza Vaccines Market and Forecast
- 5.23 India - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.23.1 India - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.23.2 India - Influenza Vaccines Market and Forecast
- 5.24 South Korea - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.24.1 South Korea - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.24.2 South Korea - Influenza Vaccines Market and Forecast
- 5.25 Thailand - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.25.1 Thailand - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.25.2 Thailand - Influenza Vaccines Market and Forecast
- 5.26 Singapore - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.26.1 Singapore - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.26.2 Singapore - Influenza Vaccines Market and Forecast
- 5.27 Hong Kong - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.27.1 Hong Kong - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.27.2 Hong Kong - Influenza Vaccines Market and Forecast
- 5.28 Malaysia - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.28.1 Malaysia - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.28.2 Malaysia - Influenza Vaccines Market and Forecast
- 5.29 Indonesia - Influenza Vaccines Market, Persons Vaccinated and Forecast
- 5.29.1 Indonesia - Number of Persons Vaccinated with Influenza Vaccines and Forecast
- 5.29.2 Indonesia - Influenza Vaccines Market and Forecast
6. Global Influenza Vaccines Market - Key Company Analysis
- 6.1 GlaxoSmithKline (GSK)
- 6.1.1 Business Overview
- 6.1.2 Influenza Vaccines Portfolio
- 6.1.3 Global - GSK Influenza Vaccines Sales and Forecast (2007 - 2030)
- 6.1.4 Promising Influenza Vaccines in the Clinical Development
- 6.1.5 Recent Developments
- 6.2 Sanofi Pasteur
- 6.2.1 Business Overview
- 6.2.2 Influenza Vaccines Portfolio
- 6.2.3 Global - Sanofi Influenza Vaccines Sales and Forecast (2009 - 2030)
- 6.2.4 Promising Influenza Vaccines in the Clinical Development
- 6.2.5 Recent Developments
- 6.3 Seqirus (CSL Limited)
- 6.3.1 Business Overview
- 6.3.2 Influenza Vaccines Portfolio
- 6.3.3 Global - Seqirus Influenza Vaccines Sales and Forecast (2016 - 2030)
- 6.3.4 Promising Influenza Vaccines in the Clinical Development
- 6.3.5 Recent Developments
- 6.4 Global - Influvac (Acquired by Abbott) Sales (2007 - 2009)
- 6.5 AstraZeneca
- 6.5.1 Business Overview
- 6.5.2 Influenza Vaccines Portfolio
- 6.5.3 Global - AstraZeneca Influenza Vaccines Sales and Forecast (2007 - 2030)
- 6.6 Gamma Vaccines Pty Ltd.
- 6.6.1 Business Overview
- 6.6.2 Influenza Vaccines Portfolio
- 6.6.3 Recent Developments
- 6.7 Hualan Bioengineering Co., Ltd.
- 6.7.1 Business Overview
- 6.7.2 Influenza Vaccines Portfolio
- 6.7.3 Recent Developments
- 6.8 Mylan (Now Part of Viatris)
- 6.8.1 Business Overview
- 6.8.2 Influenza Vaccines Portfolio
- 6.9 BioDiem
- 6.9.1 Business Overview
- 6.9.2 Influenza Vaccines Portfolio
- 6.9.3 Recent Developments
- 6.10 Shanghai Institute of Biological Products Co., Ltd.
- 6.10.1 Business Overview
- 6.10.2 Influenza Vaccines Portfolio
7. Global Influenza Vaccines Market - Emerging Players Profile
- 7.1 Novavax
- 7.1.1 Business Overview
- 7.1.2 Promising Influenza Vaccines in Clinical Development
- 7.1.3 Recent Developments
- 7.2 Medicago
- 7.2.1 Business Overview
- 7.2.2 Promising Influenza Vaccines in Clinical Development
- 7.2.3 Recent Developments
- 7.3 Moderna Inc.
- 7.3.1 Business Overview
- 7.3.2 Promising Influenza Vaccines in Clinical Development
- 7.3.3 Recent Developments
- 7.4 Pneumagen
- 7.4.1 Business Overview
- 7.4.2 Promising Influenza Vaccines in Clinical Development
- 7.4.3 Recent Developments
- 7.5 Daiichi-Sankyo
- 7.5.1 Business Overview
- 7.5.1 Influenza Vaccines Portfolio
- 7.5.2 Recent Developments
- 7.6 FluGen
- 7.6.1 Business Overview
- 7.6.2 Promising Influenza Vaccines in Clinical Development
- 7.6.3 Recent Developments
- 7.7 Imutex
- 7.7.1 Business Overview
- 7.7.2 Promising Influenza Vaccines in Clinical Development
- 7.7.3 Recent Developments
- 7.8 EpiVax
- 7.8.1 Business Overview
- 7.8.2 Promising Influenza Vaccines in Clinical Development
- 7.8.3 Recent Developments
- 7.9 Versatope Therapeutics, Inc.
- 7.9.1 Business Overview
- 7.9.2 Promising Influenza Vaccines in Clinical Development
- 7.9.3 Recent Developments
- 7.10 BiondVax Pharmaceuticals Ltd.
- 7.10.1 Business Overview
- 7.10.2 Promising Influenza Vaccines in Clinical Development
- 7.11 BIKEN Co., Ltd.
- 7.11.1 Business Overview
- 7.11.2 Influenza Vaccines Portfolio
- 7.12 Sinovac Biotech
- 7.12.1 Business Overview
- 7.12.2 Influenza Vaccines Portfolio
- 7.12.3 Recent Developments
- 7.13 Emergent BioSolutions
- 7.13.1 Business Overview
- 7.13.1 Promising Influenza Vaccines in Clinical Development
- 7.13.2 Recent Developments
- 7.14 Osivax
- 7.14.1 Business Overview
- 7.14.2 Promising Influenza Vaccines in Clinical Development
- 7.14.1 Recent Developments
- 7.15 Emergex Vaccines
- 7.15.1 Business Overview
- 7.15.2 Promising Influenza Vaccines in Clinical Development
- 7.15.3 Recent Developments
8. Global Influenza Vaccines Market - Major Deals
- 8.1 Mergers and Acquisitions
- 8.2 Licensing Agreements
- 8.3 Collaboration Agreements
9. Global Influenza Vaccines Market - Recent Developments
10. Global Influenza Vaccines Market - Driving Factors
- 10.1 Transformation of Vaccine Technologies
- 10.2 Vaccines most Cost-Effective Means of Disease Prevention
- 10.3 Scientific & Technological Breakthroughs
- 10.4 Growing Awareness and Adoption of Influenza Vaccines Due to Increasing Government Support for Immunization
- 10.5 Robust R&D Investments with Strong Pipeline Candidates to Drive Market Growth
11. Global Influenza Vaccines Market - Challenges
- 11.1 Complexity of Vaccine Development and Approval System Thwarts Product Development
- 11.1.1 Legal Obstacles
- 11.1.2 General Technical Barriers
- 11.1.3 Economic Barriers
- 11.1.4 Regulatory Barriers
- 11.2 Hurdles to Optimal use of Licensed Vaccines
- 11.2.1 Technical Obstacles
- 11.2.2 Economic Obstacles
- 11.2.3 Cultural Obstacles
- 11.3 Barriers to New Entrants in the Vaccines Market
- 11.4 Reducing the Timeline for Vaccine Development
- 11.5 Challenges Faced by Healthcare Workers in Immunization
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.